⚠️

Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.

Read our methodology →

Sharl AzarM.D.

Hematology-Oncology · Boston, MA 02114

NPI: 1114244134

Share:

42

🟠 Elevated

Risk Flags

Extreme opioid rate vs specialty peers95th percentile opioid prescribingElevated cost per beneficiaryElevated long-acting opioid rate

Risk indicators are statistical patterns, not allegations. Learn more

578

Total Claims

$217K

Drug Cost

32

Beneficiaries

$6,775

Cost/Patient

Risk Score Breakdown 42/100

Low (0)Moderate (15)Elevated (30)High (50+)
Opioid rate vs specialty peers+25
Opioid rate (national percentile)+10
Long-acting opioid rate+4
Cost per patient outlier+3

Score components are additive. Read full methodology

Peer Comparison vs. 8,541 Hematology-Oncology providers

+780%

Opioid rate vs peers

55.2% vs 6.3% avg

-50%

Cost per patient vs peers

$6,775 vs $14K avg

-4%

Brand preference vs peers

14.0% vs 14.6% avg

⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.

🔎 Data Overview

⚠️

Opioid prescribing rate is 780% above the average for Hematology-Oncology providers. While some providers legitimately treat pain-heavy populations, deviations of this magnitude are rare and warrant examination.

Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.

Opioid Prescribing

55.2%

Opioid Rate

319

Opioid Claims

$23K

Opioid Cost

40.1%

Long-Acting Rate

This provider's opioid prescribing rate of 55.2% is above the 20% threshold that CMS considers elevated.

Brand vs Generic

86% generic

Brand: 81 claims · $199K

Generic: 497 claims · $18K

Patient Profile

48

Avg Age

47%

Female

4.38

Avg Risk Score

Explore More

Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About